Phase 4
Completed N=20
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Source: ClinicalTrials.gov NCT05786521 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Lean Body Mass Change — -1730.6; -421 g
◆ Published Evidence
Emerging
11citations · ~6 / year
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
Summary
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Linked Publications
-
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lean Body Mass Change |
-1730.6; -421 | — |
Eligibility Criteria
Inclusion Criteria
- Older than 65
- Have prediabetes or diabetes
- BMI ≥ 27.0 kg/m2
- Living independently (not in assisted living or nursing home)
Exclusion Criteria
- Have heart disease
- Have liver disease
- Smoke
Data sourced from ClinicalTrials.gov (NCT05786521) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.